Intellia Therapeutics, Inc.
NTLA
$9.52
-$2.80-22.73%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 31.11% | -6.42% | 2.47% | -11.04% | -18.83% |
| Total Depreciation and Amortization | -4.81% | -0.56% | 4.06% | 13.89% | 19.77% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -66.36% | 55.01% | 16.60% | 18.86% | 56.42% |
| Change in Net Operating Assets | -167.08% | -97.75% | -34.41% | 172.61% | 695.46% |
| Cash from Operations | -71.21% | -23.43% | 8.45% | 16.32% | 35.58% |
| Capital Expenditure | 76.38% | 70.67% | 35.46% | 70.48% | 76.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 562.29% | 1,030.76% | 221.43% | -107.67% | 23.35% |
| Cash from Investing | 541.96% | 1,498.51% | 229.93% | -109.70% | 29.96% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -64.48% | -- | -97.82% | 330.28% | 1,539.35% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -64.48% | -- | -97.82% | 330.28% | 1,539.35% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 153.34% | 0.30% | 15.70% | -272.58% | 66.38% |